Related content

Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia

By  

Acta Haematologica, Vol. 134, Iss. 2, 2015-04 ,pp. : 71-75

Karger

Access to resources Recommend Favorite

Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations

By Razga Filip   Jurcek Tomas   Zackova Daniela   Dvorakova Dana   Toskova Martina   Jeziskova Ivana   Mayer Jiri   Racil Zdenek  

Molecular Diagnosis & Therapy, Vol. 16, Iss. 4, 2012-08 ,pp. : 251-259

Adis International

Access to resources Recommend Favorite

Anticipating Clinical Resistance to Target-Directed Agents: The BCR-ABL Paradigm

By Azam Mohammad   Daley George Q.  

Molecular Diagnosis & Therapy, Vol. 10, Iss. 2, 2006-01 ,pp. : 67-76

Adis International

Access to resources Recommend Favorite

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite

Analysis of surface area features of structurally diverse molecules for Bcr/Abl kinase inhibitory activity and antiproliferative activity

By Moorthy N.   Karthikeyan C.   Manivannan E.   Trivedi P.  

Medicinal Chemistry Research, Vol. 23, Iss. 5, 2014-05 ,pp. : 2622-2632

Springer Publishing Company

Access to resources Recommend Favorite